$BPMC
Blueprint Medicines Corp

2020 Q1 Form 10-Q Financial Statement

#000155837020005307 Filed on May 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $6.167M $730.0K
YoY Change 744.79% -23.48%
Cost Of Revenue $24.00K
YoY Change
Gross Profit $6.143M
YoY Change
Gross Profit Margin 99.61%
Selling, General & Admin $35.66M $16.55M
YoY Change 115.4% 67.2%
% of Gross Profit 580.42%
Research & Development $84.15M $74.25M
YoY Change 13.33% 48.5%
% of Gross Profit 1369.79%
Depreciation & Amortization $1.571M $1.178M
YoY Change 33.36% 47.25%
% of Gross Profit 25.57%
Operating Expenses $119.8M $90.80M
YoY Change 31.94% 51.68%
Operating Profit -$113.7M
YoY Change
Interest Expense $2.900M $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.703M $2.666M
YoY Change 1.39% 12.87%
Pretax Income -$111.0M -$87.40M
YoY Change 27.0% 54.69%
Income Tax
% Of Pretax Income
Net Earnings -$111.0M -$87.41M
YoY Change 26.94% 54.57%
Net Earnings / Revenue -1799.14% -11973.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.106M -$1.982M
COMMON SHARES
Basic Shares Outstanding 54.03M 44.10M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $666.8M $415.9M
YoY Change 60.32% -31.52%
Cash & Equivalents $375.2M $79.39M
Short-Term Investments $291.6M $336.5M
Other Short-Term Assets $10.10M $10.70M
YoY Change -5.61% 27.38%
Inventory $2.665M
Prepaid Expenses
Receivables $4.510M
Other Receivables $0.00
Total Short-Term Assets $704.7M $426.5M
YoY Change 65.22% -30.73%
LONG-TERM ASSETS
Property, Plant & Equipment $37.82M $107.1M
YoY Change -64.69% 268.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $83.70M
YoY Change
Other Assets $10.38M $11.00M
YoY Change -5.63% 86.44%
Total Long-Term Assets $208.9M $167.9M
YoY Change 24.47% 243.99%
TOTAL ASSETS
Total Short-Term Assets $704.7M $426.5M
Total Long-Term Assets $208.9M $167.9M
Total Assets $913.6M $594.4M
YoY Change 53.71% -10.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.468M $4.400M
YoY Change 92.45% 33.33%
Accrued Expenses $73.96M $51.59M
YoY Change 43.37% 77.27%
Deferred Revenue $8.690M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $98.29M $63.21M
YoY Change 55.48% 58.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.928M $135.7M
YoY Change -94.16% 153.17%
Total Long-Term Liabilities $7.928M $135.7M
YoY Change -94.16% 153.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $98.29M $63.21M
Total Long-Term Liabilities $7.928M $135.7M
Total Liabilities $230.7M $175.4M
YoY Change 31.55% 87.35%
SHAREHOLDERS EQUITY
Retained Earnings -$1.056B
YoY Change
Common Stock $54.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $682.9M $344.2M
YoY Change
Total Liabilities & Shareholders Equity $913.6M $544.7M
YoY Change 67.73% -18.03%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$111.0M -$87.41M
YoY Change 26.94% 54.57%
Depreciation, Depletion And Amortization $1.571M $1.178M
YoY Change 33.36% 47.25%
Cash From Operating Activities -$109.3M -$80.19M
YoY Change 36.34% 61.67%
INVESTING ACTIVITIES
Capital Expenditures $1.525M $1.770M
YoY Change -13.84% -128.1%
Acquisitions
YoY Change
Other Investing Activities $61.40M $91.10M
YoY Change -32.6% -142.81%
Cash From Investing Activities $59.86M $89.31M
YoY Change -32.98% -140.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.609M $2.039M
YoY Change -21.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 310.2M 2.011M
YoY Change 15322.68% -35.13%
NET CHANGE
Cash From Operating Activities -109.3M -80.19M
Cash From Investing Activities 59.86M 89.31M
Cash From Financing Activities 310.2M 2.011M
Net Change In Cash 260.7M 11.14M
YoY Change 2240.68% -104.19%
FREE CASH FLOW
Cash From Operating Activities -$109.3M -$80.19M
Capital Expenditures $1.525M $1.770M
Free Cash Flow -$110.9M -$81.96M
YoY Change 35.26% 89.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54168533
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49272223
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001597264
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
001-37359
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
BLUEPRINT MEDICINES CORPORATION
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3632015
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
45 Sidney Street
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2020Q1 dei City Area Code
CityAreaCode
617
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
374-7580
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2020Q1 dei Trading Symbol
TradingSymbol
BPMC
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54189964
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
375168000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113938000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
291596000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
369616000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4510000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
663000
CY2020Q1 bpmc Unbilled Receivables Including Reimbursable Costs Current
UnbilledReceivablesIncludingReimbursableCostsCurrent
20597000
CY2019Q4 bpmc Unbilled Receivables Including Reimbursable Costs Current
UnbilledReceivablesIncludingReimbursableCostsCurrent
22749000
CY2020Q1 us-gaap Inventory Net
InventoryNet
2665000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10147000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9820000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
704683000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
516786000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
83666000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
64406000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37822000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38361000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
71903000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72753000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5168000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5166000
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10381000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10222000
CY2020Q1 us-gaap Assets
Assets
913623000
CY2019Q4 us-gaap Assets
Assets
707694000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8468000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4793000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
73961000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
88706000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7169000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6823000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8690000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6160000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
98288000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
106482000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87667000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
89126000
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36809000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39913000
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7928000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7814000
CY2020Q1 us-gaap Liabilities
Liabilities
230692000
CY2019Q4 us-gaap Liabilities
Liabilities
243335000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54168533
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49272223
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
54000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1739140000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1412083000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-69000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
682931000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
464359000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
913623000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
707694000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2535000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1056194000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-945238000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6167000
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
730000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84146000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74250000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35655000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16553000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
119825000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
90803000
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2904000
CY2019Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2710000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-201000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2703000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2666000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-110955000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-87407000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2492000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
270000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108490000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87152000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.98
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52655000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44097000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
464359000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1613000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17026000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
308423000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
2492000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-110955000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
682931000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
419009000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2061000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10295000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
270000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-87407000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
344213000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-110955000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-87407000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1571000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1178000
CY2020Q1 bpmc Lease Right Of Use Asset Amortization
LeaseRightOfUseAssetAmortization
1391000
CY2019Q1 bpmc Lease Right Of Use Asset Amortization
LeaseRightOfUseAssetAmortization
1041000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16859000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10295000
CY2020Q1 bpmc Accretion Of Premiums And Discounts On Investments
AccretionOfPremiumsAndDiscountsOnInvestments
-134000
CY2019Q1 bpmc Accretion Of Premiums And Discounts On Investments
AccretionOfPremiumsAndDiscountsOnInvestments
-1332000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3847000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
323000
CY2020Q1 bpmc Increase Decrease In Customer Assets
IncreaseDecreaseInCustomerAssets
-2152000
CY2019Q1 bpmc Increase Decrease In Customer Assets
IncreaseDecreaseInCustomerAssets
219000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
382000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1408000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1381000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
66000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
114000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3715000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
982000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-16576000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1208000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-575000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-731000
CY2020Q1 bpmc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1073000
CY2019Q1 bpmc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-969000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109328000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80188000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1525000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1770000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
139250000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
112916000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
200635000
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
204000000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59860000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
89314000
CY2020Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
308541000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1609000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2039000
CY2019Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-28000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
310150000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2011000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
260682000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11137000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119604000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73429000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50000
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-16000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
380336000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84550000
CY2020Q1 bpmc Stock Issuance Costs Incurred But Not Yet Paid Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredButNotYetPaidNoncashOrPartialNoncashTransaction
118000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
465000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1478000
CY2020Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
488000
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
32000
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
53000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
375168000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79391000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5168000
CY2019Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5159000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
380336000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84550000
CY2020Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Blueprint Medicines Corporation (the Company), a Delaware corporation incorporated on October 14, 2008, is a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy. The Company’s approach is to leverage its novel target discovery engine to systematically and reproducibly identify kinases that are drivers of diseases and to craft highly selective and potent drug candidates that may provide significant and durable clinical responses for patients without adequate treatment options.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 9, 2020, the Company’s commercial product, AYVAKIT<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (avapritinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor <span style="background-color:#fefefe;color:#0a0a0a;">alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT is the first precision therapy approved to treat a genomically defined population of patients with GIST.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is devoting substantially all of its efforts to research and development, initial market development and raising capital. The Company is subject to a number of risks similar to those of other early commercial stage companies, including dependence on key individuals; establishing safety and efficacy in clinical trials for its drug candidates; the need to develop commercially viable drug candidates; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its drug candidates. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce, eliminate or out-license certain of its research and development programs or future commercialization efforts. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#212529;">On January 27, 2020, the Company closed a follow-on public offering of </span><span style="background-color:#ffffff;color:#212529;">4,710,144</span><span style="background-color:#ffffff;color:#212529;"> shares of its common stock at a price to the public of </span><span style="background-color:#ffffff;color:#212529;">$69.00</span><span style="background-color:#ffffff;color:#212529;"> per share and received estimated net proceeds of </span><span style="background-color:#ffffff;color:#212529;">$308.4</span><span style="background-color:#ffffff;color:#212529;"> million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. </span></p><p style="font-family:'Times New Roman';font-size:7pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">As of March 31, 2020, the Company had cash, cash equivalents and investments of $750.4 million. </span><span style="background-color:#ffffff;color:#212529;font-size:10pt;">Based on the Company’s current operating plans, the Company believes that its existing cash, cash equivalents and investments, together with anticipated product revenues but excluding</span><span style="font-size:10pt;"> </span><span style="background-color:#ffffff;color:#212529;font-size:10pt;">any potential option fees, milestone payments or other payments under its collaboration or license agreements, will be sufficient to enable it to fund its current operations for at least the next twelve months from the issuance of the financial statements</span><span style="font-family:'TimesNewRomanPSMT';font-size:7.5pt;">. </span></p>
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
750400000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: revenue recognition, operating lease right-of-use assets, operating lease liabilities, stock-based compensation expense, accrued expenses, and income taxes.<span style="color:#212529;font-family:'Franklin Gothic Book';"> </span>The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact thereof on local, regional, national and international customers and markets. The Company had made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</p>
CY2020Q1 bpmc Cash Equivalent And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
743997000
CY2020Q1 bpmc Cash Equivalents And Available For Sale Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
2975000
CY2020Q1 bpmc Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
746972000
CY2019Q4 bpmc Cash Equivalent And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
547454000
CY2019Q4 bpmc Cash Equivalents And Available For Sale Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
518000
CY2019Q4 bpmc Cash Equivalents And Available For Sale Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2019Q4 bpmc Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
547960000
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
11
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
82100000
CY2020Q1 bpmc Debt Securities Available For Sale Number Of Positions
DebtSecuritiesAvailableForSaleNumberOfPositions
12
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
83700000
CY2019Q4 bpmc Debt Securities Available For Sale Number Of Positions
DebtSecuritiesAvailableForSaleNumberOfPositions
9
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
64400000
CY2019Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
0
CY2020Q1 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
607000
CY2020Q1 us-gaap Contract With Customer Asset Allowance For Credit Loss Recovery
ContractWithCustomerAssetAllowanceForCreditLossRecovery
119000
CY2020Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
488000
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2580000
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
85000
CY2020Q1 us-gaap Inventory Net
InventoryNet
2665000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
5200000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
5700000
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53077000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52045000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15255000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13684000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37822000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38361000
CY2020Q1 us-gaap Depreciation
Depreciation
1600000
CY2019Q1 us-gaap Depreciation
Depreciation
1200000
CY2020Q1 bpmc External Research Development And Commercial Contract Costs Current
ExternalResearchDevelopmentAndCommercialContractCostsCurrent
51823000
CY2019Q4 bpmc External Research Development And Commercial Contract Costs Current
ExternalResearchDevelopmentAndCommercialContractCostsCurrent
59420000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9460000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13519000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9658000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
12042000
CY2020Q1 bpmc Accrued Property And Equipment Costs Current
AccruedPropertyAndEquipmentCostsCurrent
465000
CY2019Q4 bpmc Accrued Property And Equipment Costs Current
AccruedPropertyAndEquipmentCostsCurrent
906000
CY2020Q1 bpmc Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss
AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
327000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2228000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2819000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
73961000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
88706000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5795710
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.82
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1087783
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
57.21
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
127220
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.67
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
112822
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
78.82
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6643451
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
59.10
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2863027
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
43.21
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
149500000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M19D
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16900000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10300000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
17026000
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10295000
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
167000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16859000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10295000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16859000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10295000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7754908
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5763149
CY2020Q1 bpmc Coronavirus Aid Relief And Economic Security Act Taxable Income Limitation Percentage Eliminated
CoronavirusAidReliefAndEconomicSecurityActTaxableIncomeLimitationPercentageEliminated
0.80
CY2020Q1 bpmc Coronavirus Aid Relief And Economic Security Act Qualified Improvement Property Recovery Period
CoronavirusAidReliefAndEconomicSecurityActQualifiedImprovementPropertyRecoveryPeriod
P15Y
CY2020Q1 bpmc Coronavirus Aid Relief And Economic Security Act Bonus Depreciation Percentage
CoronavirusAidReliefAndEconomicSecurityActBonusDepreciationPercentage
1
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4381000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3564000
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
722000
CY2019Q1 us-gaap Sublease Income
SubleaseIncome
701000
CY2020Q1 us-gaap Lease Cost
LeaseCost
3659000
CY2019Q1 us-gaap Lease Cost
LeaseCost
2863000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3581000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2621000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
523000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
23300000
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2020Q1 us-gaap Purchase Obligation
PurchaseObligation
16200000

Files In Submission

Name View Source Status
0001558370-20-005307-index-headers.html Edgar Link pending
0001558370-20-005307-index.html Edgar Link pending
0001558370-20-005307.txt Edgar Link pending
0001558370-20-005307-xbrl.zip Edgar Link pending
bpmc-20200331xex10d1.htm Edgar Link pending
bpmc-20200331xex31d1.htm Edgar Link pending
bpmc-20200331xex31d2.htm Edgar Link pending
bpmc-20200331xex32d1.htm Edgar Link pending
bpmc-20200331xex3d1.htm Edgar Link pending
bpmc-20200506.xsd Edgar Link pending
bpmc-20200506x10q.htm Edgar Link pending
bpmc-20200506x10q_htm.xml Edgar Link completed
bpmc-20200506_cal.xml Edgar Link unprocessable
bpmc-20200506_def.xml Edgar Link unprocessable
bpmc-20200506_lab.xml Edgar Link unprocessable
bpmc-20200506_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending